BACKGROUND: We previously reported that plasminogen activator inhibitor 1 (PAI-1) was upregulated in human asthmatic airways and promotes airway fibrosis in an allergen-challenged murine model of asthma. OBJECTIVES: To examine whether elevated plasma levels of PAI-1 are associated with poor lung function in asthmatic patients. METHODS: Five hundred nineteen adults were eligible for the study, and ultimately 353 adults were enrolled and completed the baseline protocol between January 24, 2004, and July 30, 2005. Of these, 231 adults with asthma from the Chicago Initiative to Raise Asthma Health Equity study were randomly selected and the plasma levels of PAI-1 were measured by enzyme-linked immunosorbent assay. Asthma burden, medication, smoking status, and body mass index (BMI) were obtained by history and spirometry was performed. A multivariate regression analysis was performed to evaluate the association of PAI-1 levels and lung function and the potential determinant variables that were associated with PAI-1. RESULTS: We found associations between PAI-1 and BMI (β = 0.606, P = .002), smoking (β = 7.526, P = .001), and African American race (β = -9.061, P = .01). Obese patients showed a significant increase in PAI-1, and current smokers demonstrated higher levels of PAI-1 compared with nonsmokers. When we evaluated the associations between lung function parameters and PAI-1, we found that PAI-1 was negatively associated with forced vital capacity (FVC) (β = -0.098, P = .011) but not with forced expiratory volume in 1 second (FEV(1)) or the FEV(1)/FVC ratio. There was a negative association between BMI and FVC, and PAI-1 may mediate some of this association. CONCLUSIONS: This study suggests a significant association between PAI-1 and lung function in patients with asthma. The effect of obesity on FVC may in part be mediated by PAI-1.
BACKGROUND: We previously reported that plasminogen activator inhibitor 1 (PAI-1) was upregulated in human asthmatic airways and promotes airway fibrosis in an allergen-challenged murine model of asthma. OBJECTIVES: To examine whether elevated plasma levels of PAI-1 are associated with poor lung function in asthmatic patients. METHODS: Five hundred nineteen adults were eligible for the study, and ultimately 353 adults were enrolled and completed the baseline protocol between January 24, 2004, and July 30, 2005. Of these, 231 adults with asthma from the Chicago Initiative to Raise Asthma Health Equity study were randomly selected and the plasma levels of PAI-1 were measured by enzyme-linked immunosorbent assay. Asthma burden, medication, smoking status, and body mass index (BMI) were obtained by history and spirometry was performed. A multivariate regression analysis was performed to evaluate the association of PAI-1 levels and lung function and the potential determinant variables that were associated with PAI-1. RESULTS: We found associations between PAI-1 and BMI (β = 0.606, P = .002), smoking (β = 7.526, P = .001), and African American race (β = -9.061, P = .01). Obesepatients showed a significant increase in PAI-1, and current smokers demonstrated higher levels of PAI-1 compared with nonsmokers. When we evaluated the associations between lung function parameters and PAI-1, we found that PAI-1 was negatively associated with forced vital capacity (FVC) (β = -0.098, P = .011) but not with forced expiratory volume in 1 second (FEV(1)) or the FEV(1)/FVC ratio. There was a negative association between BMI and FVC, and PAI-1 may mediate some of this association. CONCLUSIONS: This study suggests a significant association between PAI-1 and lung function in patients with asthma. The effect of obesity on FVC may in part be mediated by PAI-1.
Authors: S H Cho; I P Hall; A Wheatley; J Dewar; D Abraha; J Del Mundo; H Lee; C K Oh Journal: J Allergy Clin Immunol Date: 2001-08 Impact factor: 10.793
Authors: Andreas Festa; Ralph D'Agostino; Steven S Rich; Nancy S Jenny; Russell P Tracy; Steven M Haffner Journal: Circulation Date: 2003-04-28 Impact factor: 29.690
Authors: Shawn D Aaron; Dean Fergusson; Robert Dent; Yue Chen; Katherine L Vandemheen; Robert E Dales Journal: Chest Date: 2004-06 Impact factor: 9.410
Authors: Xiao Na Ge; Yana Greenberg; M Reza Hosseinkhani; Eric K Long; Nooshin S Bahaie; Amrita Rao; Sung Gil Ha; Savita P Rao; David A Bernlohr; P Sriramarao Journal: Exp Lung Res Date: 2013-10-08 Impact factor: 2.459
Authors: Renee Rawson; Tom Yang; Robert O Newbury; Melissa Aquino; Ashmi Doshi; Braxton Bell; David H Broide; Ranjan Dohil; Richard Kurten; Seema S Aceves Journal: J Allergy Clin Immunol Date: 2016-04-08 Impact factor: 10.793
Authors: Sun H Lee; Mesut Eren; Douglas E Vaughan; Robert P Schleimer; Seong H Cho Journal: Am J Respir Cell Mol Biol Date: 2012-02-09 Impact factor: 6.914
Authors: M G Sherenian; S H Cho; A Levin; J-Y Min; S S Oh; D Hu; J Galanter; S Sen; S Huntsman; C Eng; J R Rodriguez-Santana; D Serebrisky; P C Avila; R Kalhan; L J Smith; L N Borrell; M A Seibold; L Keoki Williams; E G Burchard; R Kumar Journal: Clin Exp Allergy Date: 2017-07-03 Impact factor: 5.018
Authors: Gillian A Kelly-Robinson; James A Reihill; Fionnuala T Lundy; Lorcan P McGarvey; John C Lockhart; Gary J Litherland; Keith D Thornbury; S Lorraine Martin Journal: Int J Mol Sci Date: 2021-06-14 Impact factor: 5.923
Authors: Seong Ho Cho; Haimei Chen; Il Soo Kim; Chio Yokose; Joseph Kang; David Cho; Chun Cai; Silvia Palma; Micol Busi; Alessandro Martini; Tae J Yoo Journal: BMC Ear Nose Throat Disord Date: 2012-06-06